Les futurs traitements de la NASH

Aside from the therapies that have targeted the treatment of NonAlcoholic SteatoHepatitis (NASH) with antidiabetic agents (pioglitazone, GLP-1 receptor agonists), research is now focusing on specific therapies that we discuss in this short review. The difficulties of evaluating the effects, given the diversity of the stages of the disease, and the need to rely on robust judgment criteria, are also mentioned.